Pencadlys Ymddiriedolaeth GIG Prifysgol Felindre
Velindre University NHS Trust Headquarters
2 Cwrt Charnwood
Heol Billingsley
Parc Nantgarw
Caerdydd/Cardiff
CF15 7QZ
Ffôn/Phone : (029) 20196161
https://velindre.nhs.wales

Date: 30th July 2026
Ref: CORP 26/27 - 060

Dear xxx

Freedom of Information request: Treatment of Gastric Cancer (CORP 26/27 – 060)

Thank you for your request for information which the Trust received on 6th July 2026.

Your Request:

1. *How many patients were treated in the last 3 months with any systemic anti-cancer therapies for Gastric cancer or cancer of the Gastro-Oesophageal Junction?*

2. *How many patients were treated in the past 3 months for gastric cancer (any stage) with:*
   - *CAPOX (Capecitabine with Oxaliplatin)*
   - *FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)*
   - *Lonsurf (Trifluridine - tipiracil)*
   - *Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)*
   - *Pembrolizumab (any formulation) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)*
   - *Pembrolizumab (395 mg or 790mg solution for injection only) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)*
   - *Zolbetuximab (Vyloy)*
   - *Any other systemic anti-cancer therapy*
   - *Palliative care only*
   - *Trastuzumab in combination with cisplatin and capecitabine (or 5-fluorouracil)*
   - *Taxanes (e.g. docetaxel, paclitaxel)*
   - *Irinotecan Chemotherapy*

3. *How many patients were treated in the past 3 months for cancer of the gastro-oesophageal junction (any stage) with:*
   - *CAPOX (Capecitabine with Oxaliplatin)*
   - *FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)*
   - *Lonsurf (Trifluridine - tipiracil)*
   - *Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)*
   - *Pembrolizumab (any formulation) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)*

Pencadlys Ymddiriedolaeth GIG Prifysgol Felindre
Velindre University NHS Trust Headquarters
2 Cwrt Charnwood
Heol Billingsley
Parc Nantgarw
Caerdydd/Cardiff
CF15 7QZ
Ffôn/Phone : (029) 20196161
https://velindre.nhs.wales

- *Pembrolizumab (395 mg or 790mg solution for injection only) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)*
- *Zolbetuximab (Vyloy)*
- *Any other systemic anti-cancer therapy*
- *Palliative care only*
- *Trastuzumab in combination with cisplatin and capecitabine (or 5-fluorouracil)*
- *Taxanes (e.g. docetaxel, paclitaxel)*
- *Irinotecan Chemotherapy*

Please find the Trust's response below:

We note the same or a very similar request is being made every few months. To avoid the future use of a Qualified Exemption under Section 14(2) Freedom of Information Act 2000, the Trust suggests that you may wish to revise your periodicity of requests so that a reasonable interval has elapsed to enable the Trust to provide information to you whilst be mindful of its resources in providing such information. We recommend at least 6-9 months between requests.

Please note, the data shows number of unique patients treated with the above, as such some of these patients may have received more than one of these drugs/treatments.

1. **How many patients were treated in the last 3 months with any systemic anti-cancer therapies for Gastric cancer or cancer of the Gastro-Oesophageal Junction?**

   There have been 41 patients treated in the last 3 months.

2. **How many patients were treated in the past 3 months for gastric cancer (any stage) with:**
   - **CAPOX (Capecitabine with Oxaliplatin)** - 0
   - **FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)** - 0
   - **Lonsurf (Trifluridine - tipiracil)** - 0
   - **Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)** - 0
   - **Pembrolizumab (any formulation) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)** - 0
   - **Pembrolizumab (395 mg or 790mg solution for injection only) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)** - 0
   - **Zolbetuximab (Vyloy)** - 0
   - **Any other systemic anti-cancer therapy** - 13

Pencadlys Ymddiriedolaeth GIG Prifysgol Felindre
Velindre University NHS Trust Headquarters
2 Cwrt Charnwood
Heol Billingsley
Parc Nantgarw
Caerdydd/Cardiff
CF15 7QZ
Ffôn/Phone : (029) 20196161
https://velindre.nhs.wales

- **Palliative care only** - 16
- **Trastuzumab in combination with cisplatin and capecitabine (or 5-fluorouracil)** - 0
- **Taxanes (e.g. docetaxel, paclitaxel)** - 0
- **Irinotecan Chemotherapy** - <6*

* Where the figure provided is less than 6, and where simple calculations could identify fields that contain less than 6, the Trust has applied an exemption under Section 40(2) (personal data) of the Freedom of Information Act 2000. This is because the Trust believes there is a potential risk of individuals being able to be identified if the figures were disclosed.

3. **How many patients were treated in the past 3 months for cancer of the gastro-oesophageal junction (any stage) with:**
   - **CAPOX (Capecitabine with Oxaliplatin)**
   - **FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)**
   - **Lonsurf (Trifluridine - tipiracil)**
   - **Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)**
   - **Pembrolizumab (any formulation) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)**
   - **Pembrolizumab (395 mg or 790mg solution for injection only) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)**
   - **Zolbetuximab (Vyloy)**
   - **Any other systemic anti-cancer therapy** - <6*
   - **Palliative care only** - 8
   - **Trastuzumab in combination with cisplatin and capecitabine (or 5-fluorouracil)**
   - **Taxanes (e.g. docetaxel, paclitaxel)**
   - **Irinotecan Chemotherapy** - <6*

   * Where the figure provided is less than 6, and where simple calculations could identify fields that contain less than 6, the Trust has applied an exemption under Section 40(2) (personal data) of the Freedom of Information Act 2000. This is because the Trust believes there is a potential risk of individuals being able to be identified if the figures were disclosed.

I trust this answers your request for information, however, should you not be satisfied with the information supplied or the process of supplying it, you have a right to complain and request a review. Please note that you must submit a request for a review within 40 days of the date of this letter.

You should forward your complaint to:

Pencadlys Ymddiriedolaeth GIG Prifysgol Felindre
Velindre University NHS Trust Headquarters
2 Cwrt Charnwood
Heol Billingsley
Parc Nantgarw
Caerdydd/Cardiff
CF15 7QZ
Ffôn/Phone : (029) 20196161
https://velindre.nhs.wales

Mr Ian Bevan via FOI.VUNHST@wales.nhs.uk
Head of Information Governance
Velindre University NHS Trust
2, Charnwood Court
Heol Billingsley
Parc Nantgarw
Cardiff
CF15 7QZ

Should you wish to take your complaint further, if you are still unhappy with the decision after review, you can contact the:

Information Commissioner's Office - Wales
2nd Floor,
Churchill House,
Churchill Way,
Cardiff,
CF10 2HH
Telephone: 0330 414 6421
email: wales@ico.org.uk

Yours sincerely

Non Gwilym
Interim Director of Corporate Governance
Velindre University NHS Trust
2 Charnwood Court
Heol Billingsley
Parc Nantgarw
Cardiff
CF15 7QZ

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.